MTOR and cervical carcinoma: As several biomarkers, such as PIK3CA mutations, PTEN loss, or p-mTOR expression, have previously been proposed to select patients who are more likely to profit from mTOR inhibition, it could be hypothesized that patient selection according to future biomarkers may even improve response rates to mTOR inhibition as previously reported for cervical cancer.